EUCTR2018-004886-15-IT进行中（未招募）1 期
Evaluation of Treatment Satisfaction, Effectiveness and Tolerability in Subjects treated with Low-dose Diclofenac Epolamine Soft Capsules for Acute, Mild or Moderate Musculoskeletal Pain - DHEP soft capsules in musculoskeletal pain
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient is = or >18 years-old;
- •2.Acute mild or moderate musculoskeletal pain such as back pain, neck pain, shoulder pain, tendon or ligament pain, myalgia) started = 72 hours prior to inclusion in the trial. Pain can be either traumatic (e.g. due to an injury) or, postural/mechanical pain (e.g. due to postural strain, changes in posture or poor body mechanics, repetitive movements, prolonged immobilization);
- •3.Mild or moderate acute musculoskeletal pain to be defined at baseline as greater or equal to 20 mm and greater or equal to 60 mm on a 0-100 mm on a Visual Analogue Scale. The VAS-pain baseline assessment should be taken ensuring that no prior forbidden treatments are taken;
- •4.Informed consent obtained;
- •5.Female of childbearing potential (i.e., not permanently sterilised - post hysterectomy or tubal ligation status – or not postmenopausal) must be using an appropriate method of contraception according to the definition of Note 3 of ICH M3 Guideline during >= 30 days before inclusion and for the whole duration of the study and they must have a negative pregnancy test at Visit 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1.Musculoskeletal pain of neuropathic or post-surgical origin;
- •2.Musculoskeletal pain due to a chronic disease requiring treatment with NSAIDS for more than 3 days, according to the Investigator’s judgment;
- •3.Pain associated with chills or fever, or dysmenorrhea or endometriosis;
- •4.Current treatment with any muscle relaxant or any drugs having muscle relaxant properties either systemic or topical;
- •5.Known or suspected hypersensitivity, or intolerance to diclofenac and/or any other ingredient in the tested formulation;
- •6.Prior use of OTC or prescription NSAIDs within 36 hours of VAS-pain baseline assessment with the following exceptions:
- •-subjects with prior use of long-acting NSAIDs such as piroxicam within 72 hours before study entry or prior use of narcotic analgesics within 7 days of study entry or prior use of systemic anti-inflammatory steroidal drugs within 30 days of study entry are excluded;
- •-subjects with prior use of paracetamol < or = 1000 mg, ibuprofen < or = 400 mg, aspirin < or = 600 mg are not excluded if last dose is taken > 6 hours before the VAS assessment;
- •7.Active or suspected gastric or intestinal ulcer, bleeding or perforation and/or history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy;
- •8.History of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding);
- •9.Unexplained blood-forming disorders;
- •10.Established congestive heart failure (NYHA class II-IV), ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease;
- •11.Severe hepatic, renal or cardiac failure;
- •12.Bronchospasm, asthma, urticaria, or acute rhinitis following prior aspirin or NSAIDs intake;
- •13.Any clinical condition that, in the opinion of the Investigator, may interfere with the study drug;
- •14.Subjects participated in any other protocol involving administration of an investigational agent within 3 months before Visit 1;
- •15.Subjects pregnant or breast feeding;
- •16.Unable, in the opinion of the Investigator, to comply with the study procedures.
研究者
相似试验
已完成
Unknown
Assessing patient satisfaction following treatment with Semaglutide injection for type 2 diabetes mellitustype 2 diabetes mellitusJPRN-UMIN000053067Kimitsu Chuo Hospital103
已完成
不适用
Assessing patient satisfaction following treatment with sodium glucose co-transporter 2 inhibitor for type 1 diabetes mellitustype 1 diabetes mellitusJPRN-UMIN000040487Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital24
尚未招募
不适用
se of a new laser technique (SMILE - Small Incision lenticular extraction) to remove glasses for both near and distance visioCTRI/2019/07/020437Carl ZEISS India
已完成
不适用
Functional outcomes, treatment satisfaction, decisional regret, and the impact of institutional factors after robotic vs. retropubic radical prostatectomy: a 5 year follow-up of the HAROW studyC61Malignant neoplasm of prostateDRKS00011501Klinik und Poliklinik für UrologieTU Dresden936
已完成
不适用
Evaluation of the effect of thinning of the tip of the nose on rhinoplasty in patients with thick skiIRCT20210921052537N1Esfahan University of Medical Sciences70